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Guidelines for clinical trial protocols for interventions involving 
artificial intelligence: the SPIRIT-AI Extension
Samantha Cruz Rivera,1,2 Xiaoxuan Liu,2,3,4,5,6 An-Wen Chan,7 Alastair K Denniston,1,2,3,4,5,8  
Melanie J Calvert,1,2,6,9,10,11 On behalf of the SPIRIT-AI and CONSORT-AI Working Group
The SPIRIT 2013 (The Standard Protocol 
Items: Recommendations for 
Interventional Trials) statement aims to 
improve the completeness of clinical 
trial protocol reporting, by providing 
evidence-based recommendations for 
the minimum set of items to be 
addressed. This guidance has been 
instrumental in promoting transparent 
evaluation of new interventions. More 
recently, there is a growing recognition 
that interventions involving artificial 
intelligence need to undergo rigorous, 
prospective evaluation to demonstrate 
their impact on health outcomes.
The SPIRIT-AI extension is a new 
reporting guideline for clinical trials 
protocols evaluating interventions with 
an AI component. It was developed in 
parallel with its companion statement 
for trial reports: CONSORT-AI. Both 
guidelines were developed using a 
staged consensus process, involving a 
literature review and expert 
consultation to generate 26 candidate 
items, which were consulted on by an 
international multi-stakeholder group 
in a 2-stage Delphi survey (103 
stakeholders), agreed on in a 
consensus meeting (31 stakeholders) 
and refined through a checklist pilot 
(34 participants).
The SPIRIT-AI extension includes 15 
new items, which were considered 
sufficiently important for clinical trial 
protocols of AI interventions. These 
new items should be routinely reported 
in addition to the core SPIRIT 2013 
items. SPIRIT-AI recommends that 
investigators provide clear descriptions 
of the AI intervention, including 
instructions and skills required for use, 
the setting in which the AI intervention 
will be integrated, considerations 
around the handling of input and 
output data, the human-AI interaction 
and analysis of error cases.
SPIRIT-AI will help promote 
transparency and completeness for 
clinical trial protocols for AI 
interventions. Its use will assist editors 
and peer-reviewers, as well as the 
general readership, to understand, 
interpret and critically appraise the 
design and risk of bias for a planned 
clinical trial.
Introduction
A clinical trial protocol is an essential document 
produced by study investigators detailing a priori the 
rationale, proposed methods and plans for how a 
clinical trial will be conducted.1 2 This key document 
is used by external reviewers (funding agencies, 
regulatory bodies, research ethics committees, journal 
editors, peer reviewers and institutional review boards, 
and increasingly the wider public) to understand and 
interpret the rationale, methodological rigor and 
ethical considerations of the trial. Additionally, trial 
protocols provide a shared reference point to support 
the research team in conducting a high-quality study.
Despite their importance, the quality and complete-
ness of published trial protocols are variable.1 2 The 
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) statement was published in 
2013 to provide guidance for the minimum reporting 
content of a clinical trial protocol and has been widely 
endorsed as an international standard.3-5 The SPIRIT 
statement published in 2013 provides minimum 
guidance applicable for all clinical trial interventions, 
but recognises that certain interventions may require 
extension or elaboration of these items.1 2 Artificial 
intelligence (AI) is an area of enormous interest, 
with strong drivers to accelerate new interventions 
through to publication, implementation and market.6 
While AI systems have been researched for some 
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time, recent advances in deep learning and neural 
networks have gained significant interest for their 
potential in health applications. Examples of such 
applications of these are wide-ranging and include 
AI systems for screening and triage,7 8 diagnosis,9-12 
prognostication,13 14 decision-support15 and treatment 
recommendation.16 However, in most recent cases, 
the majority of published evidence consists of in 
silico, early-phase validation. It has been recognised 
that most recent AI studies are inadequately reported 
and existing reporting guidelines do not fully cover 
potential sources of bias specific to AI systems.17 The 
welcome emergence of randomised controlled trials 
(RCTs) seeking to evaluate clinical efficacy of newer 
interventions based on, or including, an AI component 
(hereafter ‘AI interventions’) 15 18-23 has similarly been 
met with concerns about design and reporting.17 24-26 
This has highlighted the need to provide reporting 
guidance that is ‘fit-for-purpose’ in this domain.
SPIRIT-AI (as part of the SPIRIT-AI and CONSORT-
AI initiative) is an international initiative supported 
by SPIRIT and the EQUATOR (Enhancing Quality and 
Transparency of Health Research) Network to extend 
or elaborate the existing SPIRIT 2013 statement where 
necessary, to develop consensus-based AI-specific 
protocol guidance.27 28 It is complementary to the 
CONSORT-AI statement, which aims to promote high 
quality reporting of AI trials. This article describes the 
methods used to identify and evaluate candidate items 
and gain consensus. In addition, it also provides the 
full SPIRIT-AI checklist including new items and their 
accompanying explanations.
Methods
The SPIRIT-AI and CONSORT-AI extensions were 
simultaneously developed for clinical trial protocols 
and trial reports. An announcement for the SPIRIT-AI 
and CONSORT-AI initiative was published in October 
2019,27 and the two guidelines were registered as 
reporting guidelines under development on the EQUA-
TOR library of reporting guidelines in May 2019. Both 
guidelines were developed in accordance with the 
EQUATOR Network’s methodological framework.29 The 
SPIRIT-AI and CONSORT-AI steering group, consisting 
of 15 international experts, was formed to oversee the 
conduct and methodology of the study. Definitions of 
key terms are contained in the glossary box 1.
Ethical approval
This study was approved by the ethical review 
committee at the University of Birmingham, UK 
(ERN_19-1100). Participant information was provided 
to Delphi participants electronically before survey 
completion and before the consensus meeting. Delphi 
participants provided electronic informed consent, 
and written consent was obtained from consensus 
meeting participants.
Literature review and candidate item generation
An initial list of candidate items for the SPIRIT-AI and 
CONSORT-AI checklists was generated through review 
of the published literature and consultation with the 
steering group and known international experts. A 
search was performed on 13 May 2019 using the terms 
“artificial intelligence,” “machine learning,” and 
“deep learning” to identify existing clinical trials for 
AI interventions listed within the US National Library 
of Medicine’s clinical trial registry, ClinicalTrials.gov. 
There were 316 registered trials on ClinicalTrials.gov, 
of which 62 were completed and seven had published 
results.22 30-35 Two studies were reported with reference 
to the CONSORT statement,22 34 and one study provided 
an unpublished trial protocol.34 The Operations 
Team (XL, SCR, MJC, and AKD) identified AI-specific 
considerations from these studies and reframed them 
as candidate reporting items. The candidate items were 
also informed by findings from a previous systematic 
review which evaluated the diagnostic accuracy of 
deep learning systems for medical imaging.17 After 
consultation with the steering group and additional 
international experts (n=19), 29 candidate items were 
generated: 26 of which were relevant for both SPIRIT-
AI and CONSORT-AI and three of which were relevant 
only for CONSORT-AI. The Operations Team mapped 
these items to the corresponding SPIRIT and CONSORT 
items, revising the wording and providing explanatory 
text as required to contextualise the items. These items 
were included in subsequent Delphi surveys.
Delphi consensus process
In September 2019, 169 key international experts 
were invited to participate in the online Delphi survey 
to vote on the candidate items and suggest additional 
items. Experts were identified and contacted via the 
steering group and were allowed one round of snowball 
recruitment, where contacted experts could suggest 
additional experts. In addition, individuals who made 
contact following publication of the announcement 
were included.27 The steering group agreed that 
individuals with expertise in clinical trials and AI/
ML, as well as key users of the technology should be 
well represented in the consultation. Stakeholders 
included healthcare professionals, methodologists, 
statisticians, computer scientists, industry representa-
tives, journal editors, policy makers, health infor-
maticists, law and ethicists, regulators, patients, and 
funders. Participant characteristics are described in 
the appendix (page 2: supplementary table 1). Two 
online Delphi surveys were conducted. DelphiManager 
software (version 4.0), developed and maintained by 
the COMET (Core Outcome Measures in Effectiveness 
Trials) initiative, was used to undertake the e-Delphi 
surveys. Participants were given written information 
about the study and asked to provide their level of 
expertise within the fields of (i) AI/ML, and (ii) clinical 
trials. Each item was presented for consideration (26 
for SPIRIT-AI and 29 for CONSORT-AI). Participants 
were asked to vote on each item using a 9-point scale: 
(1-3) not important, (4-6) important but not critical, 
and (7-9) important and critical. Respondents provided 
separate ratings for SPIRIT-AI and CONSORT-AI. There 
was an option to opt out of voting for each item, and 
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each item included space for free text comments. At 
the end of the Delphi survey, participants had the 
opportunity to suggest new items. One hundred and 
three responses were received for the first Delphi round, 
and 91 (88% of participants from round one) responses 
received for the second round. The results of the 
Delphi surveys informed the subsequent international 
consensus meeting. Twelve new items were proposed 
by the Delphi study participants and were added for 
discussion at the consensus meeting. Data collected 
during the Delphi survey were anonymised and item-
level results were presented at the consensus meeting 
for discussion and voting.
The two-day consensus meeting took place in January 
2020 and was hosted by the University of Birmingham, 
UK, to seek consensus on the content of SPIRIT-AI and 
CONSORT-AI. Thirty one international stakeholders 
were invited from the Delphi survey participants 
to discuss the items and vote for their inclusion. 
Participants were selected to achieve adequate 
representation from all the stakeholder groups. Thirty 
eight items were discussed in turn, comprising the 26 
items generated in the initial literature review and 
item generation phase (these 26 items were relevant 
to both SPIRIT-AI and CONSORT-AI; 3 extra items 
relevant to CONSORT-AI only were also discussed) 
and the 12 new items proposed by participants during 
the Delphi surveys. Each item was presented to the 
consensus group, alongside its score from the Delphi 
exercise (median and interquartile ranges) and any 
comments made by Delphi participants related to that 
item. Consensus meeting participants were invited to 
comment on the importance of each item and whether 
the item should be included in the AI extension. In 
Box 1: Glossary
•	Artificial	intelligence	(AI)—The science of developing computer systems which can perform tasks normally requiring 
human intelligence.
•	AI	intervention—A health intervention which relies on an artificial intelligence/machine learning component to serve 
its purpose.
•	CONSORT—Consolidated Standards of Reporting Trials.
•	CONSORT-AI	extension	item—An additional checklist item to address AI-specific content that is not adequately 
covered by CONSORT 2010.
•	Class	activation	map—Class activation maps are particularly relevant to image classification AI interventions. Class 
activation maps are visualizations of the pixels that had the greatest influence on predicted class, by displaying the 
gradient of the predicted outcome from the model with respect to the input. They are also referred to as saliency 
maps or heatmaps.
•	Health	outcome—Measured variables in the trial which are used to assess the effects of an intervention.
•	Human-AI	interaction—The process of how users/humans interact with the AI intervention, for the AI intervention to 
function as intended.
•	Clinical	outcome—Measured variables in the trial which are used to assess the effects of an intervention.
•	Delphi	study—A research method which derives the collective opinions of a group through a staged consultation of 
surveys, questionnaires, or interviews, with an aim to reach consensus at the end.
•	Development	environment—The clinical and operational settings from which the data used for training the model is 
generated. This includes all aspects of the physical setting (such as geographical location, physical environment), 
operational setting (such as integration with an electronic record system, installation on a physical device) and 
clinical setting (such as primary/secondary/tertiary care, patient disease spectrum).
•	Fine-tuning—Modifications or additional training performed on the AI intervention model, done with the intention of 
improving its performance.
•	Input	data—The data that need to be presented to the AI intervention to allow it to serve its purpose.
•	Machine	learning	(ML)—A field of computer science concerned with the development of models/algorithms which 
can solve specific tasks by learning patterns from data, rather than by following explicit rules. It is seen as an 
approach within the field of artificial intelligence.
•	Operational	environment—The environment in which the AI intervention will be deployed, including the 
infrastructure required to enable the AI intervention to function.
•	Output	data—The predicted outcome given by the AI intervention based on modelling of the input data. The output 
data can be presented in different forms, including a classification (including diagnosis, disease severity or stage, 
or recommendation such as referability), a probability, a class activation map, etc. The output data typically provides 
additional clinical information and/or triggers a clinical decision.
•	Performance	error—Instances where the AI intervention fails to perform as expected. This term can describe different 
types of failures and it is up to the investigator to specify what should be considered a performance error, preferably 
based on prior evidence. This can range from small decreases in accuracy (compared to expected accuracy), to 
erroneous predictions, or the inability to produce an output in certain cases.
•	SPIRIT—Standard Protocol Items: Recommendations for Interventional Trials.
•	SPIRIT-AI—An additional checklist item to address AI-specific content that is not adequately covered by SPIRIT 2013.
•	SPIRIT-AI	elaboration	item—Additional considerations to an existing SPIRIT 2013 item when applied to AI 
interventions.
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addition, participants were invited to comment on 
the wording of the explanatory text accompanying 
each item and the position of each item relative to the 
SPIRIT 2013 and CONSORT 2010 checklists. After 
open discussion of each item and the option to adjust 
wording, an electronic vote took place with the option 
to include or exclude the item. An 80% threshold for 
inclusion was pre-specified and deemed reasonable by 
the steering group to demonstrate majority consensus. 
Each stakeholder voted anonymously using Turning 
Point voting pads (Turning Technologies LLC, Ohio, 
USA; version 8.7.2.14).
Checklist pilot
Following the consensus meeting, attendees were 
given the opportunity to make final comments on the 
wording and agree that the updated SPIRIT-AI and 
CONSORT-AI items reflected discussions from the 
meeting. The Operations Team assigned each item 
as extension or elaboration item based on a decision 
tree and produced a penultimate draft of the SPIRIT-
AI and CONSORT-AI checklist (supplementary fig 1). 
A pilot of the penultimate checklist was conducted 
with 34 participants to ensure clarity of wording. 
Experts participating in the pilot included: a) Delphi 
participants who did not attend the consensus 
meeting and b) external experts, who had not taken 
part in the development process but who had reached 
out to the steering committee after the Delphi study 
commenced. Final changes were made on wording 
only to improve clarity for readers, by the Operations 
Team (supplementary fig 2).
Results
SPIRIT-AI checklist items and explanations
The SPIRIT-AI Extension recommends that, in 
conjunction with existing SPIRIT 2013 items, 15 
items (12 extensions and 3 elaborations) should 
be addressed for trial protocols of AI-interventions. 
These items were considered sufficiently important for 
clinical trial protocols for AI interventions that should 
be routinely reported in addition to the core SPIRIT 
2013 checklist items. Table 1 lists the SPIRIT-AI items.
All 15 items included in the SPIRIT-AI Extension 
passed the threshold of 80% for inclusion at the 
consensus meeting. SPIRIT-AI 6a (i), SPIRIT-AI 11a 
(v) and SPIRIT-AI 22 each resulted from the merging 
of two items after discussion. SPIRIT-AI 11a (iii) 
did not fulfil the criteria for inclusion based on its 
initial wording (73% vote to include); however, after 
extensive discussion and rewording, the consensus 
group unanimously supported a re-vote at which point 
it passed the inclusion threshold (97% to include).
Administrative information
SPIRIT-AI 1 (i) Elaboration: Indicate that the 
intervention involves artificial intelligence/machine 
learning and specify the type of model.
Explanation: Indicating in the protocol title and/or 
abstract that the intervention involves a form of AI 
is encouraged, as it immediately identifies the inter-
vention as an artificial intelligence/machine learning 
intervention, and also serves to facilitate indexing 
and searching of the trial protocol in bibliographic 
databases, registries, and other online resources. The 
title should be understandable by a wide audience; 
therefore, a broader umbrella term such as “artificial 
intelligence” or “machine learning” is encouraged. More 
precise terms should be used in the abstract, rather 
than the title, unless broadly recognised as being a 
form of artificial intelligence/machine learning. Specific 
terminology relating to the model type and architecture 
should be detailed in the abstract.
SPIRIT-AI 1 (ii) Elaboration: State the intended use of 
the AI intervention.
Explanation: The intended use of the AI intervention 
should be made clear in the protocol’s title and/or 
abstract. This should describe the purpose of the AI 
intervention and the disease context.19 36 Some AI 
interventions may have multiple intended uses, or 
the intended use may evolve over time. Therefore, 
documenting this allows readers to understand the 
intended use of the algorithm at the time of the trial.
Introduction
SPIRIT-AI 6a (i) Extension: Explain the intended use 
of the AI intervention in the context of the clinical 
pathway, including its purpose and its intended users 
(such as healthcare professionals, patients, public).
Explanation: In order to understand how the AI 
intervention will fit into a clinical pathway, a 
detailed description of its role should be included in 
the protocol background. AI interventions may be 
designed to interact with different users including 
healthcare professionals, patients, and the public, 
and their roles can be wide-ranging (for example, the 
same AI intervention could theoretically be replacing, 
augmenting or adjudicating components of clinical 
decision-making). Clarifying the intended use of the 
AI intervention and its intended user helps readers 
understand the purpose for which the AI intervention 
will be evaluated in the trial.
SPIRIT-AI 6a (ii) Extension: Describe any pre-existing 
evidence for the AI intervention.
Explanation: Authors should describe in the protocol 
any pre-existing published (with supporting references) 
or unpublished evidence relating to validation of the 
AI intervention, or lack thereof. Consideration should 
be given to whether the evidence was for a similar 
use, setting and target population as the planned 
trial. This may include previous development of the 
AI model, internal and external validations, and any 
modifications made before the trial.
Participants, interventions, and outcomes
SPIRIT-AI 9 Extension: Describe the onsite and 
offsite requirements needed to integrate the AI 
intervention into the trial setting.
Explanation: There are limitations to the generalisability 
of AI algorithms, one of which is when they are 
 on 28 O













J: first published as 10.1136/bm
j.m






ReseaRch Methods and RepoRting
the bmj | BMJ 2020;370:m3210 | doi: 10.1136/bmj.m3210 5
used outside of their development environment.37  38 
AI systems are dependent on their operational 
environment, and the protocol should provide details 
of the hardware and software requirements to allow 
technical integration of the AI intervention at each 
study site. For example, it should be stated if the AI 
intervention requires vendor-specific devices, if there 
is a need for specialised computing hardware at each 
site, or if the sites must support cloud integration, 
particularly if this is vendor-specific. If any changes to 
the algorithm are required at each study site as part of 
the implementation procedure (such as fine-tuning the 
algorithm on local data), then this process should also 
be clearly described.
SPIRIT-AI 10 (i) Elaboration: State the inclusion and 
exclusion criteria at the level of participants.
Explanation: The inclusion and exclusion criteria 
should be defined at the participant level as per usual 
practice in protocols of non-AI interventional trials. 
This is distinct from the inclusion and exclusion criteria 
made at the input data level, which is addressed in 
item 10 (ii).
SPIRIT-AI 10 (ii) Extension: State the inclusion and 
exclusion criteria at the level of the input data.
Explanation: Input data refer to the data required by the 
AI intervention to serve its purpose (for example, for a 
breast cancer diagnostic system, the input data could 
be the unprocessed or vendor-specific post-processing 
mammography scan on which a diagnosis is being 
made; for an early warning system, the input data could 
be physiological measurements or laboratory results 
from the electronic health record). The trial protocol 
should pre-specify if there are minimum requirements 
for the input data (such as image resolution, quality 
metrics, or data format), which would determine pre-
randomisation eligibility. It should specify when, how, 
and by whom this will be assessed. For example, if a 
participant met the eligibility criteria for lying flat for 
a CT scan as per item 10 (i), but the scan quality was 
compromised (for any given reason) to such a level that 
it is no longer fit for use by the AI system, this should 
be considered as an exclusion criterion at the input 
data level. Note that where input data are acquired 
after randomisation (addressed by SPIRIT-20c), any 
exclusion is considered to be from the analysis, not 
from enrolment (fig 1).
SPIRIT-AI 11a (i) Extension: State which version of 
the AI algorithm will be used.
Explanation: Similar to other forms of software as 
a medical device, AI systems are likely to undergo 
multiple iterations and updates in their lifespan. The 
protocol should state which version of the AI system 
will be used in the clinical trial, and whether this 
is the same version that had been used in previous 
studies to justify the study rationale. If applicable, the 
protocol should describe what has changed between 
the relevant versions and the rationale for the changes. 
Where available, the protocol should include a 
regulatory marking reference, such as a unique device 
identifier (UDI) which requires a new identifier for 
updated versions of the device.39
SPIRIT-AI 11a (ii) Extension: Specify the procedure 
for acquiring and selecting the input data for the AI 
intervention.
Explanation: The measured performance of any AI 
system may be critically dependent on the nature and 
quality of the input data.40 The procedure for how input 
data will be handled—including data acquisition, 
selection, and pre-processing before analysis by the 
AI system—should be provided. Completeness and 
transparency of this process is integral to feasibility 
assessment and to future replication of the intervention 
beyond the clinical trial. It will also help to identify 
whether input data handling procedures will be 
standardised across trial sites.
SPIRIT-AI 11a (iii) Extension: Specify the procedure 
for assessing and handling poor quality or 
unavailable input data.
Explanation: As with 10 (ii), input data refer to the data 
required by the AI intervention to serve its purpose. 
As noted in item SPIRIT-AI 10 (ii), the performance 
of AI systems may be compromised as a result of poor 
quality or missing input data41 (for example, excessive 
movement artefact on an electrocardiogram). The 
study protocol should specify if and how poor quality 
or unavailable input data will be identified and 
handled. The protocol should also specify a minimum 
standard required for the input data, and the procedure 
for when the minimum standard is not met (including 
the impact on, or any changes to, the participant care 
pathway).
Poor quality or unavailable data can also affect non-
AI interventions. For example, suboptimal quality of 
a scan could impact a radiologist’s ability to interpret 
it and make a diagnosis. It is therefore important that 
this information is reported equally for the control 
intervention, where relevant. If this minimum quality 
standard is different from the inclusion criteria for 
input data used to assess eligibility pre-randomisation, 
this should be stated.
SPIRIT-AI 11a (iv) Extension: Specify whether there 
is human-AI interaction in the handling of the input 
data, and what level of expertise is required for 
users.
Explanation: A description of the human-AI interface 
and the requirements for successful interaction when 
handling input data should be described. Examples 
include clinician-led selection of regions of interest 
from a histology slide which is then interpreted by an 
AI diagnostic system,42 or endoscopist selection of a 
colonoscopy video clip as input data for an algorithm 
designed to detect polyps.21 A description of any 
planned user training and instructions for how users 
will handle the input data provides transparency and 
replicability of trial procedures. Poor clarity on the 
human-AI interface may lead to a lack of a standard 
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Title 1 Descriptive title identifying the study design, population,  interventions, and, if applicable, trial acronym
SPIRIT-AI 1(i) 
Elaboration
Indicate that the intervention involves 
artificial intelligence/machine learning 
and specify the type of model.
SPIRIT-AI 1(ii) 
Elaboration
Specify the intended use of the AI 
intervention.
Trial registration 2a
Trial identifier and registry name. If not yet registered,  
name of intended registry
2b All items from the World Health Organization Trial Registration Data Set
Protocol version 3 Date and version identifier
Funding 4 Sources and types of financial, material, and other support
Roles and  
responsibilities
5a Names, affiliations, and roles of protocol contributors
5b Name and contact information for the trial sponsor 
5c
Role of study sponsor and funders, if any, in study design; collection, 
management, analysis, and interpretation of data; writing of the report; 
and the decision to submit the report for publication, including whether 
they will have ultimate authority over any of these activities 
5d
Composition, roles, and responsibilities of the coordinating centre, 
steering committee, endpoint adjudication committee, data  
management team, and other individuals or groups overseeing the trial, 
if applicable (see Item 21a for data monitoring committee) 
Introduction
Background and  
rationale
6a
Description of research question and justification for undertaking the  
trial, including summary of relevant studies (published and  
unpublished) examining benefits and harms for each intervention 
SPIRIT-AI 6a (i) 
Extension
Explain the intended use of the AI 
intervention in the context of the 
clinical pathway, including its purpose 
and its intended users (e.g. healthcare 
professionals, patients, public).
SPIRIT-AI 6a (ii) 
Extension
Describe any pre-existing evidence for 
the AI intervention.
6b Explanation for choice of comparators 
Objectives 7 Specific objectives or hypotheses 
Trial design 8
Description of trial design including type of trial (eg, parallel group, 
crossover, factorial, single group), allocation ratio, and framework  
(eg, superiority, equivalence, non-inferiority, exploratory) 
Methods: Participants, interventions, and outcomes
Study setting 9
Description of study settings (eg, community clinic, academic hospital) 
and list of countries where data will be collected. Reference to where list 
of study sites can be obtained 
SPIRIT-AI 9 
Extension
Describe the onsite and offsite  
requirements needed to integrate the AI 
intervention into the trial setting.
Eligibility  
criteria 10
Inclusion and exclusion criteria for participants. If applicable, eligibility 
criteria for study centres and individuals who will perform the  
interventions (eg, surgeons, psychotherapists) 
SPIRIT-AI 10 (i) 
Elaboration
State the inclusion and exclusion  
criteria at the level of participants.
SPIRIT-AI 10 (ii) 
Extension
State the inclusion and exclusion  
criteria at the level of the input data.
Interventions
11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered 
SPIRIT-AI 11a (i) 
Extension
State which version of the AI algorithm 
will be used.
SPIRIT-AI 11a (ii) 
Extension
Specify the procedure for acquiring 
and selecting the input data for the AI 
intervention.
SPIRIT-AI 11a (iii) 
Extension
Specify the procedure for assessing and 
handling poor quality or unavailable 
input data.
SPIRIT-AI 11a (iv) 
Extension
Specify whether there is human-AI inter-
action in the handling of the input data, 
and what level of expertise is required 
for users.
SPIRIT-AI 11a (v) 
Extension
Specify the output of the  
AI intervention.
SPIRIT-AI 11a (vi) 
Extension
Explain the procedure for how the AI 
intervention’s output will contribute to 
decision-making or other elements of 
clinical practice.
11b
Criteria for discontinuing or modifying allocated interventions for a 
given trial participant (eg, drug dose change in response to harms, 
participant request, or improving/worsening disease) 
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) 
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 
Outcomes 12
Primary, secondary, and other outcomes, including the specific measure-
ment variable (eg, systolic blood pressure), analysis metric (eg, change from 
baseline, final value, time to event), method of aggregation (eg, median, 
proportion), and time point for each outcome. Explanation of the clinical 
relevance of chosen efficacy and harm outcomes is strongly recommended 
Table 1 | SPIRIT-AI checklist
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Table 1 | Continued





Time schedule of enrolment, interventions (including any run-ins and 
washouts), assessments, and visits for participants. A schematic  
diagram is highly recommended (see fig 1) 
Sample size 14
Estimated number of participants needed to achieve study objectives 
and how it was determined, including clinical and statistical  
assumptions supporting any sample size calculations 
Recruitment 15 Strategies for achieving adequate participant enrolment  to reach target sample size 
Methods: Assignment of interventions (for controlled trials)
Sequence  
generation 16A
Method of generating the allocation sequence (eg, computer-generated 
random numbers), and list of any factors for stratification. To reduce 
predictability of a random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate document that is  





Mechanism of implementing the allocation sequence (eg, central telephone; 
sequentially numbered, opaque, sealed envelopes), describing any 
steps to conceal the sequence until interventions are assigned 
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 
Blinding  
(masking)
17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 
17b
If blinded, circumstances under which unblinding is permissible,  
and procedure for revealing a participant’s allocated  
intervention during the trial 
Methods: Data collection, management, and analysis
Data collection  
methods
18a
Plans for assessment and collection of outcome, baseline, and other 
trial data, including any related processes to promote data quality (eg, 
duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with their 
reliability and validity, if known. Reference to where data collection 
forms can be found, if not in the protocol 
18b
Plans to promote participant retention and complete follow-up,  
including list of any outcome data to be collected for participants  
who discontinue or deviate from intervention protocols 
Data  
management 19
Plans for data entry, coding, security, and storage, including any related 
processes to promote data quality (eg, double data entry; range checks 
for data values). Reference to where details of data management  




Statistical methods for analysing primary and secondary outcomes. 
Reference to where other details of the statistical analysis plan  
can be found, if not in the protocol 
20b Methods for any additional analyses  (eg, subgroup and adjusted analyses) 
20c
Definition of analysis population relating to protocol non-adherence (eg, 
as randomised analysis), and any statistical methods to handle missing 





Composition of data monitoring committee (DMC); summary of its role 
and reporting structure; statement of whether it is independent from the 
sponsor and competing interests; and reference to where further details 
about its charter can be found, if not in the protocol. Alternatively, an 
explanation of why a DMC is not needed 
21b
Description of any interim analyses and stopping guidelines, including 
who will have access to these interim results and make the final  
decision to terminate the trial 
Harms 22
Plans for collecting, assessing, reporting, and managing solicited and 
spontaneously reported adverse events and other unintended  
effects of trial interventions or trial conduct 
SPIRIT-AI 22 
Extension
Specify any plans to identify and  
analyse performance errors. If there are 
no plans for this, justify why not.








Plans for communicating important protocol modifications (eg, changes 
to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, 
REC/IRBs, trial participants, trial registries, journals, regulators) 
Consent or  
ascent
26a Who will obtain informed consent or assent from potential trial  participants or authorised surrogates, and how (see Item 32) 
26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable 
(Continued)
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approach and carry ethical implications, particularly 
in the event of harm.43 44 For example, it may become 
unclear whether an error case occurred due to human 
deviation from the instructed procedure or if it was an 
error made by the AI system.
SPIRIT-AI 11a (v) Extension: Specify the output of the 
AI intervention.
Explanation: The output of the AI intervention should 
be clearly defined in the protocol. For example, an 
AI system may output a diagnostic classification or 
probability, a recommended action, an alarm alerting 
to an event, an instigated action in a closed loop 
system (such as titration of drug infusions), or other. 
The nature of the AI intervention’s output has direct 
implications on its usability and how it may lead to 
downstream actions and outcomes.
SPIRIT-AI 11a (vi) Extension: Explain the procedure 
for how the AI intervention’s outputs will contribute 
to decision-making or other elements of clinical 
practice.
Explanation: Since health outcomes may also 
critically depend on how humans interact with the 
AI intervention, the trial protocol should explain how 
the outputs of the AI system are used to contribute 
to decision-making or other elements of clinical 
practice. This should include adequate description of 
downstream interventions which can impact outcomes. 
As with SPIRIT-AI 11a (iv), any elements of human-
AI interaction on the outputs should be described 
in detail. Including the level of expertise required to 
understand the outputs and any training/instructions 
provided for this purpose. For example, a skin cancer 
detection system that produces a percentage likelihood 
as output should be accompanied by an explanation of 
how this output should be interpreted and acted on by 
the user, specifying both the intended pathways (such 
as skin lesion excision if the diagnosis is positive) 
and the thresholds for entry to these pathways (such 
as skin lesion excision if the diagnosis is positive and 
the probability is >80%). The information produced 
by comparator interventions should be similarly 
described, alongside an explanation of how such 
information was used to arrive at clinical decisions for 
patient management, where relevant.
Monitoring
SPIRIT-AI 22 Extension: Specify any plans to identify 
and analyse performance errors. If there are no 
plans for this, explain why not.
Explanation: Reporting performance errors and 
failure case analysis is especially important for AI 
interventions. AI systems can make errors which may 
be hard to foresee but which, if allowed to be deployed 
at scale, could have catastrophic consequences.45 
Therefore, identifying cases of error and defining 
risk mitigation strategies are important for informing 
when the intervention can be safely implemented and 
for which populations. The protocol should specify 
whether there are any plans to analyse performance 
errors. If there are no plans for this, a justification 
should be included in the protocol.
Ethics and dissemination
SPIRIT-AI 29 Extension: State whether and how the 
AI intervention and/or its code can be accessed, 
including any restrictions to access or re-use.
Explanation: The protocol should make clear whether 
and how the AI intervention and/or its code can be 




How personal information about potential and enrolled participants will 
be collected, shared, and maintained in order to protect confidentiality 
before, during, and after the trial 
Declaration of  
interests 28
Financial and other competing interests for principal investigators for 
the overall trial and each study site 
Access to data 29
Statement of who will have access to the final trial dataset,  
and disclosure of contractual agreements that limit  
such access for investigators 
SPIRIT-AI 29 
Extension
State whether and how the AI  
intervention and/or its code can be 
accessed, including any restrictions to 
access or re-use.
Ancillary and  
post-trial care 30
Provisions, if any, for ancillary and post-trial care, and for compensation 




Plans for investigators and sponsor to communicate trial results to 
participants, healthcare professionals, the public, and other relevant 
groups (eg, via publication, reporting in results databases, or other data 
sharing arrangements), including any publication restrictions 
31b Authorship eligibility guidelines and any intended use of professional writers 




Model consent form and other related documentation  
given to participants and authorised surrogates 
Biological  
specimens 33
Plans for collection, laboratory evaluation, and storage of biological  
specimens for genetic or molecular analysis in the current trial and for 
future use in ancillary studies, if applicable
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation and Elaboration for important clarification on the items.
†Indicates page numbers to be completed by authors during protocol development.
Table 1 | Continued
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accessed or re-used. This should include details 
regarding the license and any restrictions to access.
Discussion
The SPIRIT-AI extension provides international 
consensus-based guidance on AI-specific information 
that should be reported in clinical trial protocols 
alongside SPIRIT 2013 and other relevant SPIRIT 
extensions.4 46 It comprises 15 items: three elabora-
tions to the existing SPIRIT 2013 guidance in the 
context of AI trials and 12 new extensions. The 
guidance does not aim to be prescriptive regarding the 
methodological approach to AI trials; rather it aims 
to promote transparency in reporting the design and 
methods of a clinical trial to facilitate understanding, 
interpretation, and peer review.
A number of extension items relate to the intervention 
(items 11(i-vi)), its setting (item 9), and intended role 
(item 6a (i)). Specific recommendations were made 
pertinent to AI systems relating to algorithm version, 
input and output data, integration into trial settings, 
expertise of the users, and protocol for acting on the 
AI system’s recommendations. It was agreed that these 
details are critical for independent evaluation of the 
study protocol. Journal editors reported that, despite 
the importance of these items, they are currently often 
missing from trial protocols and reports at the time of 
submission for publication, providing further weight 
to their inclusion as specifically listed extension items.
A recurrent focus of the Delphi comments and 
consensus group discussion was around safety of AI 
systems. This is in recognition that these systems, unlike 
other health interventions, can unpredictably yield 
errors which are not easily detectable or explainable 
by human judgment. For example, changes to medical 
imaging which are invisible, or appear random, to 
the human eye may change the likelihood of the 
resultant diagnostic output entirely.47  48 The concern 
is, given the theoretical ease at which AI systems 
could be deployed at scale, any unintended harmful 
consequences could be catastrophic. Two extension 
items were added to address this. SPIRIT-AI item 6a 
(ii) requires specification of the prior level of evidence 
for validation of the AI intervention. SPIRIT-AI item 
22 requires specification of any plans to analyse 
performance errors, to emphasise the importance of 
anticipating systematic errors made by the algorithm 
and their consequences.
One topic which was raised in the Delphi survey 
responses and consensus meeting, which is not 
Assessed for eligibility at participant level
Excluded (n= )
  Not meeting participant level inclusion criteria (n= )
  Declined to participate (n= )
  Other reasons (n= )
10 (i)






  Not meeting input data level inclusion criteria (n= )
  Declined to participate (n= )
  Other reasons (n= )
Enrollment
Allocated to intervention (n= )
  Received allocated intervention (n= )
  Did not receive allocated intervention (give reasons) (n= )
  Missing or inadequate input data (n= )
Allocated to intervention (n= )
  Received allocated intervention (n= )
  Did not receive allocated intervention (give reasons) (n= )
  Missing or inadequate input data (n= )
13
Follow-up
Lost to follow-up (give reasons) (n= )
  Discontinued intervention (give reasons) (n= )
  Missing or inadequate input data (n= )
Lost to follow-up (give reasons) (n= )
  Discontinued intervention (give reasons) (n= )
  Missing or inadequate input data (n= )
13
Analysis
Lost to follow-up (give reasons) (n= )
  Discontinued intervention (give reasons) (n= )
SPIRIT-AI 10 (i): State the inclusion and exclusion criteria at the level of participants
SPIRIT-AI 10 (ii): State the inclusion and exclusion criteria at the level of the input data
SPIRIT 13 (core SPIRIT item): Time schedule of enrolmnent, interventions (including any run-ins and washouts), assessments, and visits for participants.
  A schematic diagram is highly recommended
Lost to follow-up (give reasons) (n= )
  Discontinued intervention (give reasons) (n= )
Fig 1 | CONSORT 2010 flow diagram - adapted for AI clinical trials  on 28 O
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included in the final guidelines, is “continuously 
evolving” AI systems (also known as “continuously 
adapting” or “continuously learning”). These are AI 
systems with the ability to continuously train on new 
data, which may cause changes in performance over 
time. The group noted that, while of interest, this field 
is relatively early in its development without tangible 
examples in healthcare applications, and that it would 
not be appropriate for it to be addressed by SPIRIT-AI at 
this stage.49 This topic will be monitored and revisited 
in future iterations of SPIRIT-AI. It is worth noting that 
incremental software changes, whether continuous 
or iterative, intentional or unintentional, could have 
serious consequences on safety performance after 
deployment. It is therefore of vital importance that such 
changes are documented and identified by software 
version and a robust post-deployment surveillance 
plan is in place.
This study is set in the current context of AI in health; 
therefore, several limitations should be noted. First, 
at the time of SPIRIT-AI development there were only 
seven published trials and no published trial protocols 
in the field of AI for healthcare. Thus, the discussion 
and decisions made during the development of SPIRIT-
AI are not always supported by existing real-world 
examples. This arises from our stated aim to address 
the issues of poor protocol development in this field 
as early as possible, recognising the strong drivers in 
the field and the specific challenges of study design 
and reporting for AI. As the science and study of AI 
evolves, we welcome collaboration with investigators 
to co-evolve these reporting standards to ensure their 
continued relevance. Second, the literature search of AI 
RCTs used terminology such as “artificial intelligence,” 
“machine learning,” and “deep learning” but not 
terms such as “clinical decision support systems” and 
“expert systems,” which were more commonly used in 
the 1990s for technologies underpinned by AI systems 
and share similar risks with recent examples.50 It is 
likely that such systems, if published today, would be 
indexed under “AI” or “machine learning”; however, 
clinical decision support systems were not actively 
discussed during this consensus process. Third, 
the initial candidate items list was generated by a 
relatively small group of experts consisting of steering 
group members and additional international experts. 
However, additional items from the wider Delphi group 
were taken forward for consideration by the consensus 
group, and no new items were suggested during the 
consensus meeting or post-meeting evaluation.
As with the SPIRIT statement, the SPIRIT-AI 
extension is intended as a minimum reporting 
guidance, and there are additional AI-specific 
considerations for trial protocols which may warrant 
consideration (see appendix, page 2: supplementary 
table 2). This extension is particularly aimed at 
investigators planning or conducting clinical trials; 
however, it may also serve as useful guidance for 
developers of AI interventions in earlier validation 
stages of an AI system. Investigators seeking to report 
studies developing and validating the diagnostic and 
predictive properties of AI models should refer to 
TRIPOD-ML (Transparent Reporting of a Multivariable 
Prediction Model for Individual Prognosis or Diagnosis 
- Machine Learning)24 and STARD-AI (Standards for 
Reporting Diagnostic accuracy studies - Artificial 
Intelligence),51 both of which are currently under 
development. Other potentially relevant guidelines 
are registered with the EQUATOR network which are 
agnostic to study design.52 The SPIRIT-AI extension 
is expected to encourage careful early planning of AI 
interventions for clinical trials, and this, in conjunction 
with CONSORT-AI, should help to improve the quality 
of trials for AI interventions.
There is widespread recognition that AI is a rapidly 
evolving field and there will be the need to update 
SPIRIT-AI as the technology, and newer applications 
for it, develop. Currently, most applications of AI/
ML involve disease detection, diagnosis, and triage, 
and this is likely to have influenced the nature and 
prioritisation of items within SPIRIT-AI. As wider 
applications that utilise “AI as therapy” emerge, it will 
be important to re-evaluate SPIRIT-AI in the light of 
such studies. Additionally, advances in computational 
techniques and the ability to integrate them into 
clinical workflows will bring new opportunities for 
innovation that benefits patients. However, they may 
be accompanied by new challenges of study design and 
reporting to ensure transparency, minimise potential 
biases and ensure that the findings of such a study 
are trustworthy and the extent to which they may be 
generalisable. The SPIRIT-AI and CONSORT-AI Steering 
Group will continue to monitor the need for updates.
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